Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents. Weinblatt, M. E., Kremer, J. M., Cush, J. J., Rigby, W., Teng, L., Singh, N., Malamet, R. L., Genovese, M. C. WILEY-BLACKWELL. 2011: S162
View details for Web of Science ID 000297621500427